Buccal Drug Delivery Systems Market Size & Forecast Report - 2026 to 2030

The global buccal drug delivery systems market size was estimated at around USD 3 billion in 2020 and expected to witness a significant CAGR of over 9% during the forecast period 2021 to 2027. The increasing number of geriatric patients coupled with the increasing demand for easy drug delivery methods is a primary factor to drive the market growth. Furthermore, the increasing preference and continuous research and development in the field are further expected to fuel the market growth over the forecast period. Moreover, the benefits associated with the method such as rapid absorption of drugs into plasma, increasing use of smaller molecules, and availability of non-ionized drugs are expected to drive the market growth in the next upcoming years.

Market Drivers:

Advantages of Buccal Drug Delivery: Buccal drug delivery offers several advantages over traditional oral drug delivery methods. The buccal route provides direct access to the systemic circulation, bypassing the gastrointestinal tract and avoiding first-pass metabolism. This results in improved bioavailability, rapid onset of action, and enhanced therapeutic efficacy. The advantages of buccal drug delivery systems drive their adoption in the pharmaceutical industry.

Patient Convenience and Compliance: Buccal drug delivery systems offer convenience and ease of administration for patients. They eliminate the need for injections and offer a non-invasive route of drug administration. Buccal delivery also provides a discreet and user-friendly option, particularly for patients who have difficulty swallowing or require frequent dosing. The focus on patient convenience and compliance drives the demand for buccal drug delivery systems.

Increasing Demand for Controlled Drug Release: Controlled drug release is essential for achieving optimal therapeutic outcomes and minimizing adverse effects. Buccal drug delivery systems allow for controlled and sustained release of drugs, enabling better dosing control and minimizing fluctuations in drug concentrations. This controlled drug release capability drives the adoption of buccal drug delivery systems, particularly for drugs requiring precise dosage and extended release profiles.

Rising Prevalence of Chronic Diseases: The prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and neurological disorders, is on the rise globally. These conditions often require long-term medication and may benefit from targeted and controlled drug delivery. Buccal drug delivery systems provide a viable option for the continuous and controlled administration of drugs, enhancing patient management and improving therapeutic outcomes.

Advances in Drug Formulation Technologies: Technological advancements in drug formulation and delivery systems have significantly contributed to the development of effective buccal drug delivery systems. Improved formulation techniques, such as mucoadhesive polymers, nano-based drug delivery systems, and innovative drug carriers, have enhanced the efficiency, stability, and targeted drug delivery capabilities of buccal formulations. The progress in drug formulation technologies drives the growth of the buccal drug delivery systems market.

Focus on Personalized Medicine and Targeted Therapy: Personalized medicine and targeted therapy approaches aim to deliver drugs with precision and efficiency to specific target sites. Buccal drug delivery systems offer a localized and targeted drug delivery option, allowing for site-specific therapy, reducing systemic exposure, and minimizing off-target effects. The growing emphasis on personalized medicine and targeted therapy drives the adoption of buccal drug delivery systems.

Regulatory Support and Favorable Guidelines: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), provide guidelines and support for the development and approval of buccal drug delivery systems. These regulatory frameworks encourage pharmaceutical companies to invest in the development of buccal formulations and expedite the regulatory approval process. The regulatory support and favorable guidelines contribute to the growth of the buccal drug delivery systems market.

Increasing Research and Development Activities: The pharmaceutical industry is investing in research and development activities to explore innovative drug delivery methods and improve therapeutic outcomes. This includes the development of buccal drug delivery systems for various drugs and therapeutic areas. The increasing research and development activities in the field drive the advancements and adoption of buccal drug delivery systems.

Market Snapshot:

Market Insights:

The global buccal drug delivery systems market is bifurcated into type, application, end-user, and geography. On the basis of application, the market is further segmented into smoking cessation, pain management, angina pectoris, and others. the smoking cessation segment dominated the global market in 2020 and is expected to hold the largest market share of around one-third of the market by the end of the analysis period. The increasing preferences of systems and effective formulations to treat patients suffering from smoking addiction are some of the key factors driving the growth of this segment. On the other hand, the angina pectoris segment is expected to register the fastest growth rate over the forecast period.

On the basis of end-user, the market is segmented into hospitals, ambulatory centers, and others. the hospitals segment dominated the global buccal drug delivery systems market in 2020 and is expected to maintain its dominance over the forecast period. the increasing number of hospital admissions, growing geriatric patients, and the continuous research and development in the product are some major factors driving the segment growth. Furthermore, the better reimbursement facilities provided by the hospitals and the increasing investment in hospital facilities in developing economies are further expected to fuel the segment growth over the forecast period.

To know more about the report, request sample papers

The buccal drug delivery systems comprehensive study analyzes industry trends, market size, competitive analysis, and market forecast – 2021 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

The buccal drug delivery systems market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

• 2018-19 – Historical Year
• 2020 – Base Year
• 2021-2027 – Forecast Period

Market Segmentation:

By Type:

• Sublingual Films
• Buccal Tablets and Lozenges
• Oral Sprays

By Application:

• Pain Management
• Smoking Cessation
• Angina Pectoris
• Others

By End-User:

• Hospitals
• Ambulatory Centers
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage:

Geographically, North America dominated the global buccal drug delivery systems market in 2020 and is expected to hold the largest market share of around one-third of the market by the end of the analysis period. The presence of some major players coupled with the prominent investment is a major factor to drive the market in the region. Furthermore, the increasing research and development in new formulations and the increasing rate of diagnosis and treatment are further expected to fuel the market in North America. On the other hand, the growing pharmaceutical industry and the increasing geriatric population are some factors to drive the market growth at a fast pace in the Asia Pacific.

Competitive Assessment:

Some of the major market players operating in the global buccal drug delivery systems market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Indivior Pharmaceuticals, GlaxoSmithKline plc., and Catalent, Inc. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Indivior Pharmaceuticals
• GlaxoSmithKline plc.
• Catalent, Inc.
• Generex Biotechnology
• BioDelivery Sciences International, Inc.
• ARx LLC
• Endo Pharmaceuticals plc
• Cynapsus Therapeutics Inc.

Key Questions Answered by Buccal Drug Delivery Systems Market Report

• Global buccal drug delivery systems market forecasts from 2021-2027
• Regional buccal drug delivery systems market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the regions as mentioned above
• Buccal drug delivery systems submarket forecasts from 2021-2027 covering the market by type, by application, by end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about buccal drug delivery systems market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level buccal drug delivery systems markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the buccal drug delivery systems market